ES2163295T3 - Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. - Google Patents
Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.Info
- Publication number
- ES2163295T3 ES2163295T3 ES98947694T ES98947694T ES2163295T3 ES 2163295 T3 ES2163295 T3 ES 2163295T3 ES 98947694 T ES98947694 T ES 98947694T ES 98947694 T ES98947694 T ES 98947694T ES 2163295 T3 ES2163295 T3 ES 2163295T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- phenyl
- heteroaryl
- transferasa
- farnesil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Un compuesto de fórmula (1) Ar1C(R12)R13 OAr2(CH2)p-Ar 3 Fórmula (1) en la cual Ar1 representa: R5 es hidrógeno, alquilo C1-4, fenil-alquilo C1-4, R6 es hidrógeno, alquilo C1-4, hidroxi-alquilo C1-4, halo-alquilo C1-4, dihalo-alquilo C1-4, alcoxiC1-4, alcoxi C1-4 -alquilo C1-4, sulfanil-alquilo C1-4, amino-alquilo C1-4, N-(alquil C1-4)amino-alquilo C1-4, N,N-di(alquil C1-4)amino-alquilo C1-4 o fenil-alquilo C1-4; mes0,1ó 2; R12 y R13 son independientemente hidrógeno o alquilo C1-4; Ar 2 es fenilo o heteroarilo; p es0ó 1; Ar 3 es fenilo, piridinilo, piridazinilo, pirimidilo o pirazinilo, estando sustituido el anillo en los átomos de carbono del anillo por R2 y -(CH2)nR3 y en lacualAr 3 está unido a Ar 1 C(R12)R13 CH(AR2)O por un átomo de carbono del anillo; R2 es un grupo de la fórmula (2): **fórmula** en la cual R7 es hidrógeno o alquilo C1-4, R8 es -(CH2)q-R10 en cuya fórmulaq es 0-4 y R10 es alquilsulfanilo C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, hidroxi, alcoxi C1-4, carbamoílo, N-alquil C1-4carbamoílo, N,N-(dialquil C1-4)carbamoílo, alquilo C1-4, fenilo, tienilo, o alcanoil -amino C1-4, R9 es hidroxi, alcoxi C1-6, cicloalquiloxi C3-9, heterociclil-oxi, heterociclil-alcoxi C1-4 o -NH-SO2-R11 en cuya fórmula R 11 representa trifluorometilo, alquilo C1-4, fenilo, heteroarilo, aril-alquilo C1-4 o heteroarilalquilo C1-4; o R2 representa una lactona de fórmula (3) Fórmula (3) teniendo el grupo de fórmula (2) o (3) conguración L o Den el carbono quiral alfa del aminoácido libre correspondiente; n es0,1ó 2; R 3 es fenilo o heteroarilo; los anillos fenilo y heteroarilo en R3,R5,R6,R9,R11 y Ar2 están sustituidos opcionalmente de manera independiente en los átomos de carbono del anillo con hasta tres sustituyentes seleccionados de alquilo C1-4, halógeno, hidroxi, alcoxi C1-4, alcoxiC1-4-carbonilo, alcanoílo C1-4, alcanoiloxi C1-4, amino, alquilamino C1-4, di(alquil C1-4)-amino, alcanoilamino C1-4, nitro, ciano, carboxi, tiol, alquilsulfanilo C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alcano C1-4-sulfonamido, N-(alquilsulfonil C1-4)-N-alquilamino C1-4, aminosulfonilo, N-(alquil C1-4)-amino-sulfonilo, N,N-di(alquil C1-4)aminosulfonilo, carbamoílo, N-(alquil C1-4)carbamoílo, N,N-(di-alquil C1-4)-carbamoílo, carbamoil-alquilo C1-4, N-(alquil C1-4)carbamoil-alquilo C1-4, N,N-(di-alquil C1-4)carbamoil-alquilo C1-4, hidroxi-alquilo C1-4 y alcoxiC1-4alquilo C1-4, y en los grupos NH del anillo (que reemplazan hidrógeno) con alquilo C1-4, alcanoílo C1-4, alquilsulfonilo C1-4, halo-alquilo C1-4, difluorometilo o trifluorometilo; o una(o) de sus sales, profármacos o solvatos farmacéuticamente aceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97402505 | 1997-10-22 | ||
EP97402502 | 1997-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2163295T3 true ES2163295T3 (es) | 2002-01-16 |
Family
ID=26147905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98947694T Expired - Lifetime ES2163295T3 (es) | 1997-10-22 | 1998-10-19 | Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. |
Country Status (10)
Country | Link |
---|---|
US (3) | US6342765B1 (es) |
EP (1) | EP1025088B1 (es) |
JP (1) | JP2001524455A (es) |
AT (1) | ATE205195T1 (es) |
AU (1) | AU9453098A (es) |
DE (1) | DE69801590T2 (es) |
DK (1) | DK1025088T3 (es) |
ES (1) | ES2163295T3 (es) |
PT (1) | PT1025088E (es) |
WO (1) | WO1999020611A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6486156B1 (en) | 1998-12-23 | 2002-11-26 | Astrazeneca Ab | Chemical compounds |
WO2001014314A1 (fr) * | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Derives de benzene a substituants aromatiques et procedes de preparation de ceux-ci |
GB9930317D0 (en) | 1999-12-22 | 2000-02-09 | Zeneca Ltd | Novel compounds |
US6271418B1 (en) | 2000-02-22 | 2001-08-07 | Nippon Kayaku Co., Ltd. | Process for preparing (hetero) aromatic substituted benzene derivatives |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
CA2497628A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
KR101224235B1 (ko) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | 재조합 il9 항체 및 그의 용도 |
EP2272566A3 (en) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
AU2005299355A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
WO2006102095A2 (en) | 2005-03-18 | 2006-09-28 | Medimmune, Inc. | Framework-shuffling of antibodies |
AU2006261920A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Llc | Antibody formulations having optimized aggregation and fragmentation profiles |
PL2292663T3 (pl) | 2006-08-28 | 2014-03-31 | Kyowa Hakko Kirin Co Ltd | Antagonistyczne ludzkie przeciwciała monoklonalne swoiste wobec ludzkiego LIGHT |
EP2068923A4 (en) | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES |
AU2008319298B2 (en) | 2007-10-31 | 2014-07-31 | Medimmune, Llc | Protein scaffolds |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
KR102268351B1 (ko) | 2012-07-25 | 2021-06-22 | 셀덱스 쎄라퓨틱스, 인크. | 항-kit 항체 및 그의 용도 |
AU2013329311A1 (en) | 2012-10-09 | 2015-04-30 | Igenica Biotherapeutics, Inc. | Anti-C16orf54 antibodies and methods of use thereof |
AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
WO2015053871A2 (en) | 2013-08-26 | 2015-04-16 | MabVax Therapeutics, Inc. | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
HUE055189T2 (hu) | 2014-06-04 | 2021-11-29 | Biontech Res And Development Inc | Humán monoklonális antitestek a GD2 ganglioziddal ellen |
DK3229838T3 (da) | 2014-12-11 | 2020-10-19 | Pf Medicament | Anti-C10orf54-antistoffer og anvendelser deraf |
CN114504652A (zh) | 2015-03-03 | 2022-05-17 | 科马布有限公司 | 抗体、用途和方法 |
CN108925136B (zh) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体 |
CN109415437B (zh) | 2015-12-02 | 2022-02-01 | 斯特库伯株式会社 | 与btn1a1免疫特异性结合的抗体和分子及其治疗用途 |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US20200148768A1 (en) | 2017-05-31 | 2020-05-14 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
WO2018222685A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
CN110997724A (zh) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 |
EP3694889A1 (en) | 2017-10-13 | 2020-08-19 | Boehringer Ingelheim International GmbH | Human antibodies to thomsen-nouvelle (tn) antigen |
CN112740043A (zh) | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | Vista受体 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5944308B2 (ja) | 1976-03-23 | 1984-10-29 | 武田薬品工業株式会社 | ペプタイド |
US4221803A (en) * | 1979-05-09 | 1980-09-09 | Recordati, S.A. | Substituted dibenzyl ethers and pharmaceutical compositions containing said ethers for the treatment of infections |
FI803127L (fi) | 1979-10-03 | 1981-04-04 | Glaxo Group Ltd | Heterocykliska foereningar |
US4518607A (en) * | 1983-07-18 | 1985-05-21 | Syntex (U.S.A.) Inc. | Male oral contraceptive N-alkylimidazole derivatives, compositions, and method of use therefor |
US5298655A (en) | 1991-09-27 | 1994-03-29 | Merck & Co., Inc. | Farnesyl pyrophosphate analogs |
US5340828A (en) | 1991-09-30 | 1994-08-23 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5238922A (en) | 1991-09-30 | 1993-08-24 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5352705A (en) | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5326773A (en) | 1992-10-29 | 1994-07-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
HUT77406A (hu) | 1994-03-15 | 1998-04-28 | Eisai Co., Ltd., | 1-(4-Amino-5-tio-pent-2-en)-il oldalláncot tartalmazó peptidomimetikumok és az ezeket tartalmazó gyógyszerkészítmények |
CA2155448A1 (en) | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibitors of farnesyl protein transferase |
US5478934A (en) | 1994-11-23 | 1995-12-26 | Yuan; Jun | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands |
US5534537A (en) * | 1995-03-29 | 1996-07-09 | Merck & Co., Inc. | Prodrugs of inhibitors of farnesyl-protein transferase |
EP0817630A4 (en) * | 1995-03-29 | 1999-01-27 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
US5710171A (en) | 1995-05-24 | 1998-01-20 | Merck & Co., Inc. | Bisphenyl inhibitors of farnesyl-protein transferase |
GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
ES2196186T3 (es) | 1995-11-06 | 2003-12-16 | Univ Pittsburgh | Inhibidores de protein-isoprenil-transferasas. |
US6414145B1 (en) | 1997-01-29 | 2002-07-02 | Zeneca Limited | Imidazolyl compounds as inhibitors of farnesyl-protein tranferase |
-
1998
- 1998-10-19 DE DE69801590T patent/DE69801590T2/de not_active Expired - Fee Related
- 1998-10-19 EP EP98947694A patent/EP1025088B1/en not_active Expired - Lifetime
- 1998-10-19 JP JP2000516953A patent/JP2001524455A/ja not_active Withdrawn
- 1998-10-19 DK DK98947694T patent/DK1025088T3/da active
- 1998-10-19 US US09/509,210 patent/US6342765B1/en not_active Expired - Fee Related
- 1998-10-19 ES ES98947694T patent/ES2163295T3/es not_active Expired - Lifetime
- 1998-10-19 AU AU94530/98A patent/AU9453098A/en not_active Abandoned
- 1998-10-19 PT PT80103281T patent/PT1025088E/pt unknown
- 1998-10-19 WO PCT/GB1998/003117 patent/WO1999020611A1/en active IP Right Grant
- 1998-10-19 AT AT98947694T patent/ATE205195T1/de not_active IP Right Cessation
-
2001
- 2001-09-20 US US09/956,005 patent/US20020058665A1/en not_active Abandoned
- 2001-09-20 US US09/955,994 patent/US20020052376A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6342765B1 (en) | 2002-01-29 |
EP1025088A1 (en) | 2000-08-09 |
WO1999020611A1 (en) | 1999-04-29 |
PT1025088E (pt) | 2002-01-30 |
DE69801590D1 (de) | 2001-10-11 |
DE69801590T2 (de) | 2002-07-11 |
AU9453098A (en) | 1999-05-10 |
EP1025088B1 (en) | 2001-09-05 |
US20020058665A1 (en) | 2002-05-16 |
DK1025088T3 (da) | 2001-11-12 |
JP2001524455A (ja) | 2001-12-04 |
US20020052376A1 (en) | 2002-05-02 |
ATE205195T1 (de) | 2001-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2163295T3 (es) | Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. | |
BR0014133A (pt) | Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
BRPI9608082A (pt) | derivado de quinazolina, sal de cloridreto do mesmo, e, composição farmacêutica | |
EP1259487B8 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
BR0010520A (pt) | Novos compostos farmaceuticamente ativos | |
MY129540A (en) | Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect | |
BR0014116A (pt) | Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
BR0014136A (pt) | Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
NO913750L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater. | |
BR0014137A (pt) | Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
DK1326613T4 (da) | Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering | |
ME00459B (me) | Aril fuzirana azapoliciklična jedinjenja | |
DE60140814D1 (de) | N-phenyl-2-pyrimidine-amine derivatives | |
EA200501516A1 (ru) | Производные 2,3,6-тризамещённого-4-пиримидона | |
HUP0002272A2 (hu) | Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
BR0311960A (pt) | Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica | |
BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
TR200103789T2 (tr) | Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller. | |
ES2138594T3 (es) | Agentes derivados de piridina e imidazol para enfermedades cardiovasculares. | |
DE69512208T2 (de) | Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren | |
ATE287397T1 (de) | Chinoline derivate und ihre anwendung als antitumor agentien | |
ATE374366T1 (de) | Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 1025088 Country of ref document: ES |